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National Survey of Lymphedema Therapists’ Dosing of Complete Decongestive Therapy in Breast
Cancer Survivors with Lymphedema
Purpose: The purpose of this study was to identify dosing levels of complete decongestive therapy (CDT)
with survivors with Breast Cancer-Related Lymphedema (BCRL) and describe factors related to how
occupational therapists, occupational therapy assistants, physical therapists, and physical therapists assistants
with advanced lymphedema training determine dosing.
Methods: An electronic survey was sent to 598 occupational therapists, occupational therapy assistants,
physical therapists, and physical therapists assistants with training in lymphedema. Respondents completed
questions regarding demographics, dosing practices, and factors related to dose determination in complete
decongestive therapy of survivors with Breast Cancer-Related Lymphedema.
Results: 107 surveys were returned (18% response rate). Most of the respondents (95.1%) reported providing
less than the recommended daily dosing (7x/wk) of complete decongestive therapy to their survivors with
Breast Cancer-Related Lymphedema. The mean dosing of complete decongestive therapy from respondents
was approximately half of the recommended daily dosing (M=3.71). A statistically significant Pearson’s
correlation was noted among frequency of dosing and treatment adherence (r=.275) and frequency of dosing
and treatment readiness (r=.242). A multiple regression analysis found adherence accounted for a significant
proportion of variability in dosing frequency (R²=.077; F change p
Conclusions: A majority of therapists treating survivors with Breast Cancer-Related Lymphedema in an
outpatient setting are not following daily recommended dosing of complete decongestive therapy. Clinicians’
dose determination is significantly impacted by their perception of a survivor’s readiness and adherence to
lymphedema treatment and self-management. Comparative clinical outcomes studies of various therapeutic
dosage levels (times per week) and duration (length of delivery) of complete decongestive therapy are
imperative for development of best treatment protocols for survivors with Breast Cancer-Related
Lymphedema. This study serves as a first step toward evidence based planning for complete decongestive
therapy treatment of Breast Cancer-Related Lymphedema.
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Purpose: The purpose of this study was to identify dosing levels of complete decongestive therapy (CDT) with survivors with 
breast cancer-related lymphedema (BCRL) and describe factors related to how occupational therapists, occupational therapy 
assistants, physical therapists, and physical therapist assistants with advanced lymphedema training determine dosing. 
Methods: An electronic survey was sent to 598 occupational therapists, occupational therapy assistants, physical therapists, 
and physical therapist assistants with training in lymphedema. Respondents completed questions regarding demographics, 
dosing practices, and factors related to dose determination in complete decongestive therapy of survivors with BCRL. Results: 
107 surveys were returned (18% response rate). Most of the respondents (95.1%) reported providing less than the 
recommended daily dosing (7x/wk) of complete decongestive therapy to their survivors with BCRL. The mean dosing of complete 
decongestive therapy from respondents was approximately half of the recommended daily dosing (M = 3.71). A statistically 
significant Pearson’s correlation was noted among frequency of dosing and treatment adherence (r = .275) and frequency of 
dosing and treatment readiness (r = .242). A multiple regression analysis showed adherence accounted for a significant 
proportion of variability in dosing frequency (R² = .077, F change p < .05). Conclusions: A majority of therapists treating 
survivors with BCRL in an outpatient setting are not following daily recommended dosing of complete decongestive therapy. 
Clinicians’ dose determination is significantly affected by their perception of a survivor’s readiness and adherence to 
lymphedema treatment and self-management. Comparative clinical outcomes studies of various therapeutic dosage levels 
(times per week) and duration (length of delivery) of complete decongestive therapy are imperative for development of best 
treatment protocols for survivors with BCRL. This study serves as a first step toward evidence-based planning for complete 
decongestive therapy treatment of BCRL. 
 
BACKGROUND 
A woman in the United States has about a 1 in 8 chance of developing breast cancer in her lifetime, and men with breast 
cancer gene (BRCA1 or BRCA2) have a 1 in 100 or 6 in 100 chance, respectively, of developing breast cancer in their 
lifetimes.1, 2 Even more alarming is that many of the 2.8 million breast cancer survivors living in the United States today are 
living with lymphedema, a chronic non-curable side effect of breast cancer treatment.3 Breast cancer-related lymphedema 
(BCRL) is an abnormal accumulation of protein-rich fluid in the interstitial spaces that can lead to chronic inflammation of 
tissues; swelling of the limb, shoulder girdle, breast, or thoracic region; or a combination of any of these.4 Chronic lymphedema 
can lead to impairment in upper extremity function, ultimately affecting a survivor’s daily occupational performance in activities 
of daily living (ADL).5 Regardless of the stage, severity, or etiology, most survivors are treated similarly with complete 
decongestive therapy (CDT), which has been found to likely be effective in a systematic review of the literature.6,7 
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Traditional complete decongestive therapy for chronic lymphedema consists of two phases: an intensive phase (phase I), 
performed by a therapist with advanced lymphedema training and a maintenance phase (phase II) that transitions the patient 
to self-management of lymphedema at home. The intensive phase has a recommended standardized protocol, focusing on 
meticulous skin and nail care, manual lymphatic drainage, compression bandaging, and remedial exercises, and is 
recommended to be dosed daily by a trained therapist until maximal volume reduction and normalization of tissue texture is 
achieved.8 After a review of literature in dosing of CDT, study protocols varied significantly between both number of days per 
week and overall duration of treatment provided. For the purposes of this study, dosing in lymphedema management is the 
frequency of treatment (times per week) as opposed to overall time (minutes of treatment) and duration of treatment. 
 
Due to multiple limitations of the United States health care system, including reimbursement of therapy services, the number 
of out-of-pocket patient expenses, and caps on therapy treatment, therapists with advanced lymphedema training likely are 
struggling to provide the recommended daily outpatient dosing of intensive phase I CDT to survivors. An investigation of the 
daily lymphedema reduction patterns during the CDT intensive phase showed the most substantial lymphedema reduction 
occurs within the first 3 days of treatment.9 Similarly, in two studies, the most significant reduction in limb volume was 
achieved during the first week of treatment.10, 11 These results have been used to support shortening the CDT intensive 
treatment phase to reduce economic burden of the patients. 
 
Although CDT is supported by efficacy studies, the daily dosing recommendation was developed using level five evidence and 
is anecdotal rather than evidence-based practice. Knowledge of potential factors that influence CDT outcomes could assist 
clinicians in developing plans of care and need to be further explored.7 The wide range of selected dosing of CDT in studies 
and the lack of comparative dosing within studies demonstrates a need for effective protocol development for best survivorship 
care. Studies for comparing dosing for effective CDT protocols and factors influencing dose determination have not yet been 
performed. Therefore, research is necessary to determine the current state of CDT practice and factors that affect dose 
determination in the United States. 
 
In the literature, CDT has varied dosing from 1 time per week to 7 times per week; therefore, research efforts are indicated to 
explore the state of CDT practice today and factors associated with dose determination, which will allow for a better 
understanding of current practice and the potential need for further efficacy studies for dose comparison. The primary purpose 
of this study was to identify lymphedema trained therapists’ dosing levels (times per week) of phase I CDT with survivors with 
BCRL. The secondary purpose was to describe factors related to how therapists determine dosing of phase I CDT for survivors 
with BCRL. Specifically, the frequency (times per week) of phase I CDT dosing provided by lymphedema therapists is 






A survey was developed for occupational therapists, occupational therapy assistants, physical therapists, and physical therapist 
assistants with advanced training in lymphedema that assessed participant demographics, dosing practices, and factors related 
to dose determination in phase I treatment using CDT for survivors with BCRL. The survey consisted of four sections assessing 
current practice on dosing of CDT and factors related to dose determination. A combination of questions that used fixed response 
options, Likert scales, and free text comments were used in the design: (1) Demographic information (6 items of fixed response 
options and free text comments), (2) current CDT dosing practice (three items of fixed response options and free text comments), 
(3) perceptions on client factors that inhibit provision of intended plan of care (10 Likert-scale items), and (4) perceptions about 
organizational factors that inhibit provision of intended plan of care (4 Likert-scale items). 
 
Survey Instrument Development 
To assure the survey design met the needs of the respondents and to check face validity, a pretest of the survey was 
performed before dissemination. This pretest was used for researchers to identify potential problems with intent, clarity, and 
navigation.12 The pretesting process for developing the questionnaire was conducted using recommended steps.13 Five 
certified lymphedema therapists (2 occupational therapists and 3 physical therapists) working with survivors with BCRL were 
given the survey via paper and contacted for a telephone interview. The therapists were asked to first answer the questions 
just as if they were research participants, then conversation was opened to critiques of the preliminary version of the survey. 
Information gleaned from these pretests was incorporated into minor changes for the final survey, and changes were approved 
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Nonprobability and snowball sampling approaches were utilized through the first investigator's professional networks, including 
personal network of colleagues, the National Lymphedema Network conference attendee list, and the American Occupational 
Therapy Association’s professional networking site. Those therapists with a background in physical or occupational therapy with 
advanced training in lymphedema were asked to participate. 
 
Procedures 
REDCap software Version 5.8.2, an online survey development and data collection secure Web application, was utilized.14 
Therapists were emailed an invitation to participate in the study, and a direct link to the online survey was included. Informed 
consent was provided as the front page of the survey, and participants’ submission indicated their consent. To address non- 
response error, surveys were distributed to possible participants twice as a reminder strategy.12 The survey results were 
analyzed using IBM SPSS Version 22 (IBM Corporation, Armonk, NY). The data were analyzed using descriptive statistics 





Six hundred forty-four practitioners were initially invited to complete the survey; 46 surveys were returned as undeliverable, 
resulting in 598 potential participants. One hundred and seven responded to the survey for a response rate of 18%. All 
respondents but 4 were female with an average age of approximately 46 years old (M = 45.78, SD + 9.720). Most of the 
respondents (81.1%, n = 90) reported having a master’s degree or lower for their educational background. The average 
number of years respondents practiced was almost 9 years (M = 8.94, SD + 2.927). Table 1 presents respondents’ 
demographics and further professional characteristics. 
Table 1. Respondent Demographics, Credentials, Educational Background, and Years of Practice 
Demographics, Credentials, & Years of Practice n Valid Percent 
Gender   
Male 4 4.4 
Female 86 95.6 
Ethnicity   
Caucasian 83 92.2 
African-American 4 4.4 
Hispanic 0 0 
Asian 2 2.2 
Pacific Islander 1 1.1 
Credentials   
Occupational Therapy Assistant 1 1.1 
Occupational Therapist 33 36.7 
Physical Therapist Assistant 6 6.7 
Physical Therapist 45 50.0 
Certified Lymphedema Therapist 59 65.6 
LANA Certified Therapist 51 56.7 
Educational Background   
Associate’s Degree 1 1.1 
Bachelor’s Degree 39 43.3 
Master’s Degree 32 35.6 
Clinical Doctorate 17 18.9 
 M SD 
Age 45.78 9.720 
Year of Practice 8.94 2.927 
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Response to Dose Provision 
Most of the respondents (95.1%) reported providing less than the recommended daily dosing (7x/wk) of CDT to their patients 
with BCRL. Specifically, the mean dosing of complete decongestive therapy was 3.71 times per week with a standard deviation 
of 1.35. Figure 1 depicts the group frequency distribution related to dose provision. 
 
 
Figure 1. Histogram of Mean and Standard Deviation of Treatment Dosing 
 
Perceived Factors Affecting Dose Determination 
The top perceived factors indicated by respondents as most affecting CDT dose determination included the clients’ schedule 
(M = 8.03, SD + 2.06), client’s transportation availability (M = 7.90, SD + 2.33), and client’s readiness for treatment (M = 7.50, 
SD + 2.58). The factors indicated by respondents as having the least effect on CDT dose determination include not enough 
lymphedema trained clinicians (M = 3.91, SD = 3.55), organizational policies (M = 3.50, SD + 3.58), and organizational culture 
(M = 2.92, SD + 3.37). Table 2 depicts the mean responses and standard deviation related to perceived factors affecting CDT 
dose determination. 
 
Correlation of Perceived Factors Related to CDT Dosing 
A statistically significant Pearson’s correlation was noted among frequency of dosing and treatment adherence (r = .275) 
and treatment readiness (r = .242). Table 2 depicts the correlations of each of the perceived factors affecting CDT dosing. 
 
Regression of Perceived Factors Related to CDT Dosing 
A forward, stepwise, multiple regression analysis was performed to clarify the relationships between the two correlated 
perceived factors and frequency of dosing. The regression analyses only included outpatient therapists because a 
disproportionate respondent distribution was noted within therapists practice setting with significantly more respondents from 
an outpatient setting. By itself, adherence accounted for a significant proportion of the variability in dosing frequency (R² = 
.077, F change P = .042). However, adding readiness to this predictive model did not improve the overall amount of variability 
explained (Adjusted R² = .054; F change =.042, F change p = .717). Thus, it appears that the significant correlation between 
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readiness and dosing maybe due to an underlying correlation between readiness and adherence. Table 2 depicts the 
correlation regression statistics. 
Table 2. Mean, Standard Deviation, and Pearson Correlation of Perceived Factors Affecting Dose Determination 
Factor M SD Correlation (r) 
Volume in UE 7.40 3.008 .095 
Symptoms 7.00 2.879 .176 
Other Diagnoses 5.92 2.785 .160 
Patient Supports 7.46 2.442 .187 
Patient Schedule 8.03 2.064 -.008 
Availability of Transportation 7.90 2.326 .124 
Patient Readiness 7.50 2.580 .242* 
Patient Adherence 7.37 2.486 .275* 
Insurance 6.26 3.616 .088 
Patient Finances 6.50 3.226 -.031 
Therapists Availability 5.30 3.790 .033 
Organizational Culture 2.92 3.370 -.123 
Organizational Policies 3.50 3.584 -.051 
Staffing 3.91 3.549 -.118 
Correlation is significant at the 0.05 level (2-tailed). 
* Correlation is significant at the 0.01 level (2-tailed).** 
 
DISCUSSION 
The primary purpose of this study was to identify lymphedema trained therapists’ provision of dosing levels (times per week) 
of CDT for patients with BCRL. While traditional protocols call for intensive phase I complete decongestive therapy (CDT) that 
includes daily dosing, this study’s findings indicated that around 95% of therapists are not providing this recommended protocol 
in the United States. The average rate of dosing reported was just over half the recommended dosing at 3.71 days per week. 
When ranges in frequency of dosing were reported by respondents, the highest value reported was used with the assumption 
that a range reflects the fact that this treatment is intended to taper overtime. Respondents’ frequency of CDT dose delivery 
ranged from 1 time per week to 7 times per week. 
 
It is still unknown whether the dosing found in this study is the appropriate amount to create maximum therapeutic benefit, thus 
further studies are needed comparing the effectiveness of different frequencies of dosing (times per week) and duration of 
dosing (length of delivery) for the provision of the most evidence-based protocol recommendations. This recommendation was 
supported by several researchers in concluding that longer-term follow-up studies are needed to determine optimal treatment 
protocols of CDT.7, 15, 16 Holtgrefe found that twice weekly dosing with a higher dosing frequency similar to 5 days per week is 
needed.17 This study showed that phase I CDT dosing varies so widely that future studies will also need to explore other dosing 
variables beyond 2 and 5 times a week. It has also been recommended by Yamamoto et al that for future randomized controlled 
trials, researchers should consider reducing phase I of CDT and also consider therapeutic effects to optimize use of limited 
financial resources.9 
Physical therapist assistants (PTA) were included as participants because they may perform the dosing recommended by their 
supervising physical therapist. Of important note, this study was conducted under the assumption that therapists were adhering 
to all components of phase I CDT practice (skin and nail care, manual lymphatic drainage, compression bandaging, remedial 
exercises, and self-care training). Researchers have found that lymphedema treatment itself (components of treatment, such 
as manual lymphatic drainage, bandaging, and garments) vary significantly.18 This study was not focused on treatment content 
nor specific clinical outcomes for the patients. Thus, research is also needed to study individual components of treatment along 
with differing combinations of treatments in order to more accurately develop optimal treatment protocol recommendations. 
The secondary purpose of this study was to determine factors related to how therapists with advanced lymphedema training 





© The Internet Journal of Allied Health Sciences and Practice, 2018 
determine dosing of CDT for survivors with BCRL. Top factors perceived by therapists as affecting their dosing were all client 
factors: availability of transportation, patients’ schedule, and patient readiness. The factors that were perceived by therapists 
as least influential in dose determination were all organizational factors: staffing, organizational policies, and organizational 
culture. Thus, organizational barriers are not perceived as affecting dose determination in lymphedema survivorship care. The 
distribution of these factors was slightly skewed, which may be a function of the Likert scale used in assessment. 
 
It is not surprising that our study indicated a disproportionate respondent distribution because generally the United States 
health care system model is not supportive of inpatient lymphedema treatment. Statistically significant correlations provided 
evidence that a survivor’s readiness and adherence to treatment affect therapists’ dose determination. Patients with chronic 
diseases such as BCRL must possess a readiness for management and treatment of their condition or disease progression 
and non-adherence can be consequences. 20 Both adherence and readiness factors are imperative for self-management of 
chronic conditions such as lymphedema. The regression analysis showed adherence to account for approximately 8% of the 
predictive model. Thus, continued studies are needed to further explore additional factors that might explain the remaining 
variation in therapists’ dose determination. Reserchers should add a survey validation process into their methods and focus 
on patients’ perceptions of dose determination to potentially account for more of the predictive model. 
 
Lymphedema therapists who perceived self-management factors of adherence and readiness as issues affecting provision of 
CDT dosing more often selected a higher frequency of CDT dosing to their patients. Self-management ultimately is imperative 
to reduce exacerbations of swelling, prevent infection, and manage other symptoms associated with lymphedema. 21 Thus, it 
is not surprising that the higher the therapists scored on the self-perceived factors of self-management, the higher the dosing 
they provide to their patients. Although clinicians are indicating that self-management factors influence the dosing of CDT they 
provide, there is little evidence on which to make recommendations for self-management. 21 Further studies are warranted to 
explore patient’s perceptions of dosing factors. Patient perspectives on which factors are most important to support self-
management strategies should also be explored. 
This study indicated that clinicians are considering self-management factors, such as readiness and adherence to treatment, 
which affect dose determination in phase I of CDT. The average adherence to BCRL self-care is not adequate. 22 Additional 
researchers have recommended further exploration of the role of patients’ adherence to maintenance of their self-
management programs. 7, 19 Therapists working with survivors should consider each patient’s lymphedema self-management 




This study has several limitations based on the utilization of the nonprobability sampling approach. Primarily, the sample was 
limited to the National Lymphedema Network conference attendee list and other nonprobability sampling; therefore, it may not 
be representative of all therapists with advanced training in lymphedema practicing within the United States. This study’s 
response rate, however, did fall between recommended liberal and stringent conditions required for survey response rates. 23 
The participants were all therapists providing treatment to survivors with BCRL, thus the respondents might have had an 
elevated interest in the topic. Additionally, this study can only provide the therapists’ perspectives, which may differ from the 
survivors. 
Although the survey instrument was developed after a thorough literature review and feedback was incorporated from pretesting 
the instrument with experts in the field, a formal validation process was not completed. The use of closed-ended questions and 
a Likert scale (range of 0-10) with a ceiling may have limited the scope of participant’s responses. 
 
CONCLUSION 
This study indicated that a majority of practicing occupational therapists, occupational therapy assistants, physical therapists, 
and physical therapist assistants with advanced lymphedema training in outpatient settings in the United States are not 
following daily recommended dosing in phase I CDT. Additionally, clinicians’ dose determination is significantly affected by 
their perception of a survivor’s external supports, readiness, adherence to lymphedema treatment and self-management of 
this chronic condition. Practicing clinicians with advanced lymphedema training need to be mindful of the dosing they provide 
survivors with BCRL and continue to individually tailor dosing based on patient needs until further research explorations provide 
evidence for guidance. Future research is recommended to determine the most effective dosing for phase I CDT to improve 
survivorship outcomes. Furthermore, researchers should explore survivor’s readiness for treatment and its effect on adherence 
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to treatment as well as overall lymphedema self-management strategies for a more holistic approach to this chronic disease. 
Future researchers have the potential to determine if clinicians need to consider initially monitoring for survivor’s supports, 
readiness, and adherence factors to minimize their impact on clinician dose determination in phase I of CDT. 
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